Computational Metagenomic Analysis Reveals Microbial Imbalances in Chronic Prostatitis

Overview

This study utilized nanopore-based 16S rRNA sequencing to characterize microbial communities and antibiotic resistance gene profiles in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients. Bacillus velezensis was identified as a dominant species with potential pathogenic and antibiotic-like metabolite properties, highlighting new therapeutic targets.

Background

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a complex urological condition with poorly understood etiology and limited effective treatments. Traditional antibiotic use has been widespread despite unclear microbial causes, contributing to antimicrobial resistance. Recent advances in high-throughput sequencing, especially nanopore technology, enable detailed analysis of microbial communities and resistance genes in CP/CPPS. Understanding microbial imbalances and their role in inflammation may inform targeted therapies and improve patient outcomes.

Data Highlights

Key Findings

• Bacillus velezensis identified as a dominant bacterial species in CP/CPPS patients, marking its first association with the condition.
• B. velezensis possesses secondary metabolites with antibiotic-like properties, potentially contributing to microbial competition and chronic inflammation.
• Antibiotic resistance genes, including those conferring resistance to vancomycin and pleuromutilin, were detected in dominant bacterial populations.
• Nanopore sequencing enabled real-time, high-accuracy microbial genome assembly, surpassing traditional short-read methods.
• Microbial imbalances and ARG profiles varied across age groups but consistently implicated Bacillus dominance in CP/CPPS pathology.
• Bioinformatics platforms BV-BRC and Galaxy facilitated comprehensive analysis of microbial metabolic pathways and virulence factors relevant to CP/CPPS.

Clinical Implications

These findings suggest that targeted antibiotic therapy guided by metagenomic profiling could improve treatment efficacy and reduce recurrence in CP/CPPS. Identification of Bacillus velezensis and its resistance patterns supports the need for personalized antimicrobial strategies rather than empirical antibiotic use. Furthermore, understanding microbial contributions to inflammation may open avenues for novel anti-inflammatory or microbiome-modulating therapies.

Conclusion

Metagenomic analysis using nanopore sequencing reveals critical microbial imbalances and resistance gene profiles in CP/CPPS, with Bacillus velezensis emerging as a key pathogen. These insights provide a foundation for developing precise, targeted treatments to address this challenging condition.

References

1. NIH Category III Criteria -- Chronic Prostatitis Classification
2. Bilge Hospital Urology Department Study -- Sample Collection Protocols
3. Oxford Nanopore Technologies -- 16S rRNA Sequencing Kit
4. BV-BRC and Galaxy Bioinformatics Platforms -- Microbial Analysis Tools
5. Recent Reviews on CP/CPPS and Microbiome -- Pathogenesis and Treatment